Finfeed: Follow our investments in early stage, ASX listed biotech and life sciences stocks.
Finfeed has teamed up with one of Australia’s most successful early stage biotech and life sciences fund managers to select and invest in stocks that we believe have a high chance of success. We then share our research, analysis and investment strategies with our readers.
From the team that brought you Next Investors, Wise-Owl and Catalyst Hunter investment portfolios.
Follow our investment portfolio of small cap, ASX listed biotech stocks by subscribing below:
Our Current Portfolio of Investments
| Company |
Current Price |
First Coverage |
5 Day VWAP |
VWAP Returns
|
Our Entry Price
|
Our Returns |
News | |
|---|---|---|---|---|---|---|---|---|
|
Date
|
Price
|
|||||||
| $0.310 | 16-Aug-21 | $0.400 | $0.348 | -11% | $0.200 | 55% |
|
|
| $0.000 | 30-Sep-21 | $0.000 | $0.000 | % | $0.000 | % |
|
|
| $0.000 | 15-Oct-21 | $0.000 | $0.000 | % | $0.000 | % |
|
|
| $0.000 | 15-Nov-21 | $0.000 | $0.000 | % | $0.000 | % |
|
|
|
ASX:DXB
|
Our Current Returns 55% |
|
ASX:???
|
Our Current Returns % |
|
ASX:???
|
Our Current Returns % |
|
ASX:???
|
Our Current Returns % |
Subscribe to access new portfolio additions:
The past performance is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.